Sage Therapeutics Inc. (SAGE) and Sol-Gel Technologies Ltd. (NASDAQ:SLGL) Comparison side by side

Sage Therapeutics Inc. (NASDAQ:SAGE) and Sol-Gel Technologies Ltd. (NASDAQ:SLGL) compete against each other in the Biotechnology sector. We will contrast them and contrast their risk, analyst recommendations, profitability, dividends, earnings and valuation, institutional ownership.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Sage Therapeutics Inc. 90.00M 82.12 283.92M -6.40 0.00
Sol-Gel Technologies Ltd. N/A 410.01 25.78M -1.45 0.00

Table 1 highlights Sage Therapeutics Inc. and Sol-Gel Technologies Ltd.’s top-line revenue, earnings per share (EPS) and valuation.


Table 2 provides us Sage Therapeutics Inc. and Sol-Gel Technologies Ltd.’s return on equity, return on assets and net margins.

Net Margins Return on Equity Return on Assets
Sage Therapeutics Inc. -315.47% -31.5% -29.8%
Sol-Gel Technologies Ltd. 0.00% -54% -37.9%


Sage Therapeutics Inc.’s Current Ratio is 19.1 while its Quick Ratio is 19.1. On the competitive side is, Sol-Gel Technologies Ltd. which has a 16 Current Ratio and a 16 Quick Ratio. Sage Therapeutics Inc. is better positioned to pay off short and long-term obligations compared to Sol-Gel Technologies Ltd.

Analyst Recommendations

Sage Therapeutics Inc. and Sol-Gel Technologies Ltd. Recommendations and Ratings are available in the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Sage Therapeutics Inc. 1 0 2 2.67
Sol-Gel Technologies Ltd. 0 0 0 0.00

Sage Therapeutics Inc. has a consensus target price of $184.67, and a 17.15% upside potential.

Institutional & Insider Ownership

Roughly 0% of Sage Therapeutics Inc. shares are owned by institutional investors while 25.7% of Sol-Gel Technologies Ltd. are owned by institutional investors. About 0.1% of Sage Therapeutics Inc.’s share are owned by insiders. On the other hand, insiders owned about 71.84% of Sol-Gel Technologies Ltd.’s shares.


In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Sage Therapeutics Inc. -6.71% -17.26% -33.17% -27.69% 17.03% -34.7%
Sol-Gel Technologies Ltd. -8.4% -20.49% -18.21% -29.45% 0% -55.21%

For the past year Sage Therapeutics Inc.’s stock price has smaller decline than Sol-Gel Technologies Ltd.


Sage Therapeutics Inc. beats on 6 of the 10 factors Sol-Gel Technologies Ltd.

Sage Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel medicines to treat central nervous system disorders. Its lead product candidate includes SAGE-547, a proprietary intravenous formulation of allopregnanolone that is in Phase III clinical development as an adjunctive therapy for the treatment of super-refractory status epilepticus (SRSE), as well as for the treatment of post-partum depression (PPD). The companyÂ’s product pipeline includes SAGE-217, a novel neuroactive steroid, which is in Phase II clinical trials for the treatment of PPD, major depressive disorders, essential tremor, and ParkinsonÂ’s diseases; and SAGE-689 a novel positive allosteric modulator of GABAA receptors that is in preclinical stage for the treatment of status epilepticus. In addition, its product pipeline that are in preclinical stage comprises SAGE-105, a novel neuroactive steroid for the treatment of orphon epilepsies; SAGE-324, a novel neuroactive steroid for the treatment of GABA hypofunction; and SAGE-718, a novel oxysterol-based positive allosteric modulator of NMDA receptors for the treatment of cerebrosterol deficit disorders, anti-NMDA receptor encephalitis, and NMDA hypofunction. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Sol-Gel Technologies Ltd., a clinical-stage specialty pharmaceutical company, focuses on developing and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel. The company's lead product candidates include TWIN and SIRS-T, which has completed Phase II clinical trials for the treatment of acne vulgaris; and VERED that has completed Phase II clinical trials for the treatment of papulopustular rosacea. It is also involved in the development of generic dermatological drug products. Sol-Gel Technologies Ltd. has collaboration with Perrigo; and Douglas Pharmaceuticals for the development and commercialization of a generic product candidate. The company was founded in 1997 and is headquartered in Ness Ziona, Israel.